MODERATE RISK OF HEPATITIS B VIRUS REACTIVATION IN HBsAg-/HBcAb+ CARRIERS RECEIVING RITUXIMAB FOR RHEUMATOID ARTHRITIS

被引：0
|
作者：
Kuo, Meng Hsuan [1 ]
Tseng, Chi-Wei [2 ]
Lee, Chi-Hui [1 ]
机构：
[1] Dalin Tzu Chi Hosp, Pharm, Chiayi, Taiwan
[2] Tzuchi Univ, Sch Med, Hualien, Taiwan
来源：
HEPATOLOGY | 2019年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1028
引用
收藏
页码：624A / 624A
页数：1
相关论文
共 50 条
  • [1] Moderate Risk of Hepatitis B Virus Reactivation in HBsAg-/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis
    Kuo, Meng Hsuan
    Tseng, Chih-Wei
    Lee, Chi-Hui
    Tung, Chien-Hsueh
    Tseng, Kuo-Chih
    Lai, Ning-Sheng
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [2] Moderate Risk of Hepatitis B Virus Reactivation in HBsAg−/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis
    Meng Hsuan Kuo
    Chih-Wei Tseng
    Chi-Hui Lee
    Chien-Hsueh Tung
    Kuo-Chih Tseng
    Ning-Sheng Lai
    Scientific Reports, 10
  • [3] Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis
    Hong, Xuezhi
    Xiao, Yanhua
    Xu, Liyan
    Liu, Lei
    Mo, Hailu
    Mo, Hanyou
    IMMUNITY INFLAMMATION AND DISEASE, 2023, 11 (02)
  • [4] Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis
    Tien, Y. -C.
    Yen, H. -H.
    Chiu, Y. -M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2017, 35 (05) : 831 - 836
  • [5] HBV reactivation in HBsAg-/HBcAb plus rheumatoid arthritis patients receiving biologic/targeted synthetic DMARDs
    Kuo, Meng Hsuan
    Tseng, Chih-Wei
    Ko, Ping-Hung
    Wang, Sz-Tsan
    Lu, Ming-Chi
    Tung, Chien-Hsueh
    Tseng, Kuo-Chih
    Huang, Kuang-Yung
    Lee, Chi-Hui
    Lai, Ning-Sheng
    LIVER INTERNATIONAL, 2024, 44 (02) : 497 - 507
  • [6] LOW RISK OF HEPATITIS B VIRUS REACTIVATION IN HBsAg NEGATIVE, ANTI-HBc POSITIVE CARRIERS UNDERGOING RITUXIMAB FOR RHEUMATOID ARTHRITIS
    Vigano, M.
    Varisco, V.
    Lampertico, P.
    Batticciotto, A.
    Mascheroni, A.
    Gibertini, P.
    Pellerito, R.
    Rovera, G.
    Caporali, R.
    Todoerti, M.
    Covelli, M.
    Notarnicola, A.
    Colombo, M.
    Sarzi-Puttini, P.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S287 - S288
  • [7] LOW RISK OF HEPATITIS B VIRUS REACTIVATION IN HBSAG NEGATIVE, ANTI-HBC POSITIVE CARRIERS UNDERGOING RITUXIMAB FOR RHEUMATOID ARTHRITIS
    Vigano, M.
    Varisco, V.
    Lampertico, P.
    Batticciotto, A.
    Marchesoni, A.
    Gibertini, P.
    Pellerito, R.
    Rovera, G.
    Caporali, R.
    Todoerti, M.
    Covelli, M.
    Notarnicola, A.
    Colombo, M.
    Sarzi-Puttini, P.
    DIGESTIVE AND LIVER DISEASE, 2014, 46 : E23 - E23
  • [8] Hepatitis B reactivation in HBsAg-/cAb plus patients receiving rituximab: A meta-analysis
    Mozessohn, Lee
    Chan, Kelvin K.
    Feld, Jordan J.
    Hicks, Lisa K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study
    Varisco, Valentina
    Vigano, Mauro
    Batticciotto, Alberto
    Lampertico, Pietro
    Marchesoni, Antonio
    Gibertini, Patrizia
    Pellerito, Raffaele
    Rovera, Guido
    Caporali, Roberto
    Todoerti, Monica
    Covelli, Michele
    Notarnicola, Antonella
    Atzeni, Fabiola
    Sarzi-Puttini, Piercarlo
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (05) : 869 - 874
  • [10] REACTIVATION OF HEPATITIS B INFECTION IN HAEMATOLOGY PATIENTS RECEIVING RITUXIMAB THERAPY: EVIDENCE OF SUB-CLINICAL ALT FLARES IN HBSAG-/HBCAB plus PATIENTS
    Mackenzie, S.
    Cheeseman, S.
    Waters, L.
    Scully, M.
    Ardeshna, K.
    Linch, D.
    Lambert, J.
    HAEMATOLOGICA, 2015, 100 : 476 - 476
12345